Hansa Biopharma announces submission of IND Application to US FDA for HNSA-5487 in GBS
- The IND submission marks an important milestone in advancing Hansa’s novel IgG-cleaving enzyme into clinical development in GBS.
Lund, Sweden, October 20, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for HNSA-5487, Hansa’s novel IgG-cleaving enzyme, to support clinical development in Guillain-Barré syndrome (GBS).
